市場調査レポート

商品コード

1318758

神経障害性疼痛治療薬市場：タイプ別、治療法別、適応症別、診断別、流通別、エンドユーザー別-2023-2030年の世界予測

Neuropathic Pain Drug Market by Type, Treatment, Indication, Diagnosis, Distribution, End User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

出版日: 2023年06月12日 | 発行: 360iResearch

| ページ情報: 英文 195 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF, Excel & Online Access - 1 Year (Single User License)

USD 4,749 746,257円

レポートPDF及びExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Up to 5 User License)

USD 5,749 903,397円

レポートPDF及びExcelを5名まで共有ご利用頂けるライセンスです。ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Site License)

USD 6,749 1,060,537円

レポートPDF及びExcelを同一事業所（所在地）内のすべての方でご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Enterprise User License)

USD 8,749 1,374,817円

レポートPDF及びExcelを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

ご注意事項 :

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

神経障害性疼痛治療薬の世界市場は、2023年に115億3,000万米ドル、CAGR 9.75%で大幅な成長が予測され、2030年には221億6,000万米ドルという驚異的な規模に達する見込みです。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の神経障害性疼痛治療薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.神経障害性疼痛治療薬の世界市場規模および予測は？

2.予測期間中、世界の神経障害性疼痛治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.神経障害性疼痛治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.神経障害性疼痛治療薬の世界市場における競争戦略は？

5.神経障害性疼痛治療薬の世界市場における技術動向と規制の枠組みは？

6.神経障害性疼痛治療薬の世界市場における主要ベンダーの市場シェアは？

7.神経障害性疼痛治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

市場力学
- 促進要因
  - 糖尿病やがんなどの慢性疾患の有病率が世界的に増加
  - 世界中でヘルスケアシステムがますます進歩
  - 小売薬局では多数の承認済み医薬品が入手可能
- 抑制要因
  - 死に至る可能性のある副作用の可能性
- 機会
  - 新興国における神経因性疼痛に関する意識の高まり
  - 続く技術革新と医薬品の開発
- 課題
  - 不完全な鎮痛に対する懸念
市場動向
COVID-19の累積的な影響
ロシア・ウクライナ紛争の累積的影響
高インフレの累積的影響
ポーターのファイブフォース分析
バリューチェーンとクリティカルパス分析
規制の枠組み
顧客のカスタマイズ

第6章神経障害性疼痛治療薬市場：タイプ別

幻肢痛
帯状疱疹後神経痛
外傷後神経障害
三叉神経痛

第7章神経障害性疼痛治療薬市場治療別

抗うつ薬の種類
- セロトニンノルアドレナリン
- 三環系抗うつ薬
薬の種類
集学的治療法
NSAIDの種類
- イブプロフェン
- ナプロキセン

第8章神経障害性疼痛治療薬市場適応症別

糖尿病性神経障害
脊柱管狭窄症

第9章神経障害性疼痛治療薬市場診断別

血液検査
画像健康診断
- 臨床試験
- 筋電図検査
- MRI

第10章神経障害性疼痛治療薬市場配信別

オンライン薬局
小売薬局およびドラッグストア

第11章神経障害性疼痛治療薬市場：エンドユーザー別

クリニック
病院

第12章南北アメリカの神経障害性疼痛治療薬市場

アルゼンチン
ブラジル
カナダ
メキシコ
米国

第13章アジア太平洋地域の神経障害性疼痛治療薬市場

オーストラリア
中国
インド
インドネシア
日本
マレーシア
フィリピン
シンガポール
韓国
台湾
タイ
ベトナム

第14章欧州・中東・アフリカの神経障害性疼痛治療薬市場

デンマーク
エジプト
フィンランド
フランス
ドイツ
イスラエル
イタリア
オランダ
ナイジェリア
ノルウェー
ポーランド
カタール
ロシア
サウジアラビア
南アフリカ
スペイン
スウェーデン
スイス
トルコ
アラブ首長国連邦
英国

第15章競合情勢

FPNVポジショニングマトリクス
市場シェア分析：主要企業別
競合シナリオ分析：主要企業別

第16章掲載企業一覧

第17章付録

ディスカッションガイド
ライセンスと価格について

図表

LIST OF FIGURES

FIGURE 1. NEUROPATHIC PAIN DRUG MARKET RESEARCH PROCESS
FIGURE 2. NEUROPATHIC PAIN DRUG MARKET SIZE, 2022 VS 2030
FIGURE 3. NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 5. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2022 VS 2030 (%)
FIGURE 6. NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 7. NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2022 VS 2030 (%)
FIGURE 8. NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
FIGURE 9. NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2022 VS 2030 (%)
FIGURE 10. NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 11. NEUROPATHIC PAIN DRUG MARKET DYNAMICS
FIGURE 12. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 16. NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 22. NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 23. NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

TABLE 1. NEUROPATHIC PAIN DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 5. NEUROPATHIC PAIN DRUG MARKET SIZE, BY PHANTOM LIMB PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 6. NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST HERPETIC NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-TRAUMATIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 10. NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 11. NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. NEUROPATHIC PAIN DRUG MARKET SIZE, BY SEROTONIN NORADRENALINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. NEUROPATHIC PAIN DRUG MARKET SIZE, BY MEDICATION TYPE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. NEUROPATHIC PAIN DRUG MARKET SIZE, BY MULTIMODAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 17. NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. NEUROPATHIC PAIN DRUG MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. NEUROPATHIC PAIN DRUG MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 21. NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPINAL STENOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 24. NEUROPATHIC PAIN DRUG MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 26. NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. NEUROPATHIC PAIN DRUG MARKET SIZE, BY CLINICAL TRIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. NEUROPATHIC PAIN DRUG MARKET SIZE, BY ELECTROMYOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. NEUROPATHIC PAIN DRUG MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 31. NEUROPATHIC PAIN DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. NEUROPATHIC PAIN DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 66. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 68. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 70. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 71. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 72. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 80. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 81. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 108. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 112. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 114. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 115. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 117. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 118. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 119. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 121. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 122. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 123. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 124. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 126. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 127. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 128. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 130. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 131. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 132. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 133. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 135. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 140. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 141. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 142. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 144. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 145. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 146. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 148. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 149. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 150. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 151. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 152. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 153. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 158. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 159. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 160. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 162. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 163. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 166. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 167. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 168. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 169. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 171. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 172. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 175. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 176. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 177. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 178. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 179. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 180. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 181. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 184. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 185. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 187. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 188. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 193. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 194. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 195. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 196. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 197. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 198. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 199. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 200. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 202. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 203. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 204. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 205. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 206. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 207. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 208. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 221. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 222. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 223. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 224. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 225. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 226. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 227. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 228. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 230. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 231. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 232. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 233. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 234. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 235. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 236. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 237. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 239. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 240. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 241. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 242. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 243. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 244. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 245. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 246. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 248. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 249. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 250. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 251. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 252. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 253. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 254. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 255. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 257. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 258. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 259. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 260. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 261. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 262. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 263. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 264. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 275. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 276. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 277. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 278. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 279. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 280. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 281. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 282. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 293. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 294. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 295. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 296. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 297. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 298. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 299. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 300. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 302. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 303. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 304. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 305. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 306. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 307. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 308. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 309. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 311. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 312. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 313. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 314. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 315. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 316. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 317. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 318. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 320. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 321. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 322. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 323. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 324. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 325. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 326. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 327. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 328. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 329. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 330. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 331. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 332. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 333. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 334. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2030 (USD MILLION)
TABLE 335. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 336. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 337. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 338. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 339. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 340. SAUDI ARABIA NEUROPATHIC PAIN DRUG

Product Code: MRR-036C5CF3B4DF

The Global Neuropathic Pain Drug Market is forecasted to grow significantly, with a projected USD 11.53 billion in 2023 at a CAGR of 9.75% and expected to reach a staggering USD 22.16 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Neuropathic Pain Drug Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Neuropathic Pain Drug Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy, and Trigeminal Neuralgia. The Phantom Limb Pain is projected to witness significant market share during forecast period.

Based on Treatment, market is studied across Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type is further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type is further studied across Ibuprofen and Naproxen. The NSAIDs Type is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Diabetic Neuropathy and Spinal Stenosis. The Diabetic Neuropathy is projected to witness significant market share during forecast period.

Based on Diagnosis, market is studied across Blood Tests and Imaging Physical Examination. The Imaging Physical Examination is further studied across Clinical Trial, Electromyography, and MRI. The Imaging Physical Examination is projected to witness significant market share during forecast period.

Based on Distribution, market is studied across Online Pharmacies and Retail Pharmacies & Drug Stores. The Retail Pharmacies & Drug Stores is projected to witness significant market share during forecast period.

Based on End User, market is studied across Clinics and Hospitals. The Clinics is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Neuropathic Pain Drug Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Neuropathic Pain Drug Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neuropathic Pain Drug Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neuropathic Pain Drug Market?

4. What is the competitive strategic window for opportunities in the Global Neuropathic Pain Drug Market?

5. What are the technology trends and regulatory frameworks in the Global Neuropathic Pain Drug Market?

6. What is the market share of the leading vendors in the Global Neuropathic Pain Drug Market?

7. What modes and strategic moves are considered suitable for entering the Global Neuropathic Pain Drug Market?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Neuropathic Pain Drug Market, by Type, 2022 vs 2030
4.3. Neuropathic Pain Drug Market, by Treatment, 2022 vs 2030
4.4. Neuropathic Pain Drug Market, by Indication, 2022 vs 2030
4.5. Neuropathic Pain Drug Market, by Diagnosis, 2022 vs 2030
4.6. Neuropathic Pain Drug Market, by Distribution, 2022 vs 2030
4.7. Neuropathic Pain Drug Market, by End User, 2022 vs 2030
4.8. Neuropathic Pain Drug Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing prevalence of chronic diseases such as diabetes and cancer globally
  - 5.1.1.2. Rising advancement of healthcare systems across the world
  - 5.1.1.3. Availability of numerous approved drugs at retail pharmacies
- 5.1.2. Restraints
  - 5.1.2.1. Probable side effects that could lead to death
- 5.1.3. Opportunities
  - 5.1.3.1. Surge in awareness related to neuropathic pain in emerging economies
  - 5.1.3.2. Ongoing technological innovations and development of drugs
- 5.1.4. Challenges
  - 5.1.4.1. Concerns over incomplete pain relief
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Neuropathic Pain Drug Market, by Type

6.1. Introduction
6.2. Phantom Limb Pain
6.3. Post Herpetic Neuralgia
6.4. Post-traumatic Neuropathy
6.5. Trigeminal Neuralgia

7. Neuropathic Pain Drug Market, by Treatment

7.1. Introduction
7.2. Antidepressant Drugs Type
- 7.2.1. Serotonin Noradrenaline
- 7.2.2. Tricyclic Antidepressants
7.3. Medication Type
7.4. Multimodal Therapy
7.5. NSAIDs Type
- 7.5.1. Ibuprofen
- 7.5.2. Naproxen

8. Neuropathic Pain Drug Market, by Indication

8.1. Introduction
8.2. Diabetic Neuropathy
8.3. Spinal Stenosis

9. Neuropathic Pain Drug Market, by Diagnosis

9.1. Introduction
9.2. Blood Tests
9.3. Imaging Physical Examination
- 9.3.1. Clinical Trial
- 9.3.2. Electromyography
- 9.3.3. MRI

10. Neuropathic Pain Drug Market, by Distribution

10.1. Introduction
10.2. Online Pharmacies
10.3. Retail Pharmacies & Drug Stores

11. Neuropathic Pain Drug Market, by End User

11.1. Introduction
11.2. Clinics
11.3. Hospitals

12. Americas Neuropathic Pain Drug Market

12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Neuropathic Pain Drug Market

13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam

14. Europe, Middle East & Africa Neuropathic Pain Drug Market

14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom

神経障害性疼痛治療薬市場：タイプ別、治療法別、適応症別、診断別、流通別、エンドユーザー別-2023-2030年の世界予測

Neuropathic Pain Drug Market by Type, Treatment, Indication, Diagnosis, Distribution, End User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

FPNVポジショニング・マトリックス

市場シェア分析

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

第6章 神経障害性疼痛治療薬市場：タイプ別

第7章 神経障害性疼痛治療薬市場治療別

第8章 神経障害性疼痛治療薬市場適応症別

第9章 神経障害性疼痛治療薬市場診断別

第10章 神経障害性疼痛治療薬市場配信別

第11章 神経障害性疼痛治療薬市場：エンドユーザー別

第12章 南北アメリカの神経障害性疼痛治療薬市場

第13章 アジア太平洋地域の神経障害性疼痛治療薬市場

第14章 欧州・中東・アフリカの神経障害性疼痛治療薬市場

第15章 競合情勢

第16章 掲載企業一覧

第17章 付録